|
|
Researchers from Spain said data collected from 1.3 million vaccinated individuals in Catalonia who received the Pfizer and AstraZeneca jabs had about the same number of clotting incidents, EuroNews reported.
The news outlet obtained a “pre-print” paper on the subject from Barcelona’s IDIAP Jordi Gol institute that has not been peer-reviewed. The study included 1,372, 213 people who were vaccinated with the two vaccines and found “similar safety profiles.”
“In general, rates of thrombosis after vaccination with a first dose of [AstraZeneca] were similar to those seen after a first dose of [Pfizer/BioNTech], although with fewer study participants having received this vaccine, there was greater uncertainty around estimates,” the researchers wrote.
The recent report said the study found that those who came down with COVID-19 had “a far higher rate” of blood clots than those who developed the condition after the jabs.
The study found the risk of deep vein thrombosis and pulmonary embolism about 1.3 times higher for those who were vaccinated than the general public. The report said the study found those with the virus have eight times the risk of developing venous thromboembolism.
The report said of 222,710 COVID-19 patients in the study, 499 developed blood clots. Under normal conditions, there would be 62 cases.
Yet, despite these facts, on Sunday, the boy playing Australia’s chief medical officer, Michael Kidd declared “The benefits of the Covid-19 vaccine AstraZeneca are greater than the risk of the rare side effects occurring, in all age groups.”
TRENDPOST: AstraZeneca has suffered from a barrage of negative press due to blood clot concerns, allowing the Pfizer Jab—which we note in this Trends Journal as being only 50 percent effective—to firmly secure the unofficial title of the Cadillac of COVID-19 vaccines.
In the 9 February Trends Journal and subsequent issues, we have been reporting on problems associated with the AstraZeneca COVID vaccine. We had noted that Switzerland’s health agency said it would not administer the Oxford/AstraZeneca COVID-19 vaccine because the data “available and evaluated to date [is] not yet sufficient.” And in May, Norway banned the use of the AstraZeneca COVID-19 shot due to harmful side-effects.